Dideoxyguanosine, also known as ddG or 2',3'-dideoxyguanosine, is a nucleoside analog of guanosine that plays a significant role in antiviral and antiretroviral therapies, particularly in the treatment of HIV. Its chemical structure features a guanine base attached to a sugar moiety that lacks both the 2' and 3' hydroxyl groups, which is crucial for its function as a chain-terminating agent during DNA synthesis. This absence of hydroxyl groups prevents the addition of further nucleotides, thereby inhibiting viral replication. Dideoxyguanosine is typically administered in its phosphate form, which is converted into the active triphosphate form within cells. It exhibits a relatively low toxicity profile compared to other nucleoside analogs, although it can still cause side effects such as bone marrow suppression and peripheral neuropathy. The compound is classified under the category of antimetabolites and is utilized in combination therapies to enhance efficacy against resistant viral strains. Its CAS number, 85326-06-3, is a unique identifier that facilitates its recognition in chemical databases and regulatory contexts.

Dideoxyguanosine

85326-06-3: 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide - 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one (1:1), 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one, 2′,3′-Dideoxyguanosine, Dideoxyguanosine, Guanosine, 2',3'-dideoxy-, Guanosine, 2′,3′-dideoxy-

CAS 85326-06-3: Dideoxyguanosine

2',3'-Dideoxyguanosine

Ref: 54-BID2036

2-Amino-9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one

Ref: 10-F212038

2-Amino-9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one

Ref: IN-DA004P8A

2'',3''-Dideoxyguanosine

Ref: 7W-GN2446

2',3'-Dideoxyguanosine

Ref: 3B-D6107

2',3'-Dideoxyguanosine

Ref: 3D-ND04069